MEK1/2 Antibody - #AF6385

>>买2送1 已结束>>
>>赠JD卡 已结束>>
(36)   (22)  
产品: MEK1/2 抗体
货号: AF6385
描述: Rabbit polyclonal antibody to MEK1/2
应用: WB IHC IF/ICC
文献验证: WB, IHC
反应: Human, Mouse, Rat
预测: Pig, Zebrafish, Bovine, Horse, Sheep, Rabbit, Dog, Chicken, Xenopus
蛋白号: Q02750 | P36507
RRID: AB_2835226

浏览相似产品>>

   规格 价格 库存
 50ul RMB¥ 1250 现货
 100ul RMB¥ 2300 现货
 200ul RMB¥ 3000 现货

货期: 当天发货

联系销售
相关下载
MSDS
说明书
COA
实验方案
WB Handbook
IHC Protocol
IF/ICC Protocol

产品描述

来源:
Rabbit
应用:
WB 1:500-1:2000, IHC 1:50-1:200, IF/ICC 1:100-1:500
*The optimal dilutions should be determined by the end user.
*Tips:

WB: 适用于变性蛋白样本的免疫印迹检测. IHC: 适用于组织样本的石蜡(IHC-p)或冰冻(IHC-f)切片样本的免疫组化/荧光检测. IF/ICC: 适用于细胞样本的荧光检测. ELISA(peptide): 适用于抗原肽的ELISA检测.

反应:
Human, Mouse, Rat
克隆:
Polyclonal
特异性:
MEK1/2 Antibody detects endogenous levels of total MEK1/2.
RRID:
AB_2835226
引用格式: Affinity Biosciences Cat# AF6385, RRID:AB_2835226.
偶联:
Unconjugated.
纯化:
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
保存:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
别名:

展开/折叠

Dual specificity mitogen activated protein kinase kinase 1; Dual specificity mitogen-activated protein kinase kinase 1; ERK activator kinase 1; MAP kinase kinase 1; MAP kinase/Erk kinase 1; MAP2K1; MAPK/ERK kinase 1; MAPKK 1; MAPKK1; MEK 1; Mek1; MEKK1; Mitogen activated protein kinase kinase 1; MKK 1; MKK1; MP2K1_HUMAN; PRKMK1; Protein kinase mitogen activated kinase 1 (MAP kinase kinase 1); Protein kinase mitogen activated, kinase 1; Cardiofaciocutaneous syndrome; CFC syndrome; CFC4; Dual specificity mitogen activated protein kinase kinase 2; Dual specificity mitogen-activated protein kinase kinase 2; ERK activator kinase 2; FLJ26075; MAP kinase kinase 2; map2k2; MAPK / ERK kinase 2; MAPK/ERK kinase 2; MAPKK 2; MAPKK2; MEK 2; MEK2; Microtubule associated protein kinase kinase 2; Mitogen activated protein kinase kinase 2; Mitogen activated protein kinase kinase 2 p45; MKK 2; MKK2; MP2K2_HUMAN; OTTHUMP00000165826; OTTHUMP00000165827; PRKMK 2; PRKMK2;

抗原和靶标

免疫原:

A synthesized peptide derived from human MEK1/2, corresponding to a region within the internal amino acids.

基因/基因ID:
MAP2K1(5604) | MAP2K2(5605)
描述:
The protein encoded by this gene is a member of the dual specificity protein kinase family, which acts as a mitogen-activated protein (MAP) kinase kinase. MAP kinases, also known as extracellular signal-regulated kinases (ERKs), act as an integration point for multiple biochemical signals.

研究领域

· Cellular Processes > Cell growth and death > Oocyte meiosis.   (View pathway)

· Cellular Processes > Transport and catabolism > Autophagy - animal.   (View pathway)

· Cellular Processes > Cell growth and death > Apoptosis.   (View pathway)

· Cellular Processes > Cell growth and death > Cellular senescence.   (View pathway)

· Cellular Processes > Cellular community - eukaryotes > Focal adhesion.   (View pathway)

· Cellular Processes > Cellular community - eukaryotes > Gap junction.   (View pathway)

· Cellular Processes > Cellular community - eukaryotes > Signaling pathways regulating pluripotency of stem cells.   (View pathway)

· Cellular Processes > Cell motility > Regulation of actin cytoskeleton.   (View pathway)

· Environmental Information Processing > Signal transduction > MAPK signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > ErbB signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > Ras signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > Rap1 signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > cGMP-PKG signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > cAMP signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > HIF-1 signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > FoxO signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > Sphingolipid signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > Phospholipase D signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > mTOR signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > PI3K-Akt signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > Apelin signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > TNF signaling pathway.   (View pathway)

· Human Diseases > Drug resistance: Antineoplastic > EGFR tyrosine kinase inhibitor resistance.

· Human Diseases > Drug resistance: Antineoplastic > Endocrine resistance.

· Human Diseases > Neurodegenerative diseases > Prion diseases.

· Human Diseases > Substance dependence > Alcoholism.

· Human Diseases > Infectious diseases: Viral > Hepatitis B.

· Human Diseases > Infectious diseases: Viral > Influenza A.

· Human Diseases > Infectious diseases: Viral > Human papillomavirus infection.

· Human Diseases > Cancers: Overview > Pathways in cancer.   (View pathway)

· Human Diseases > Cancers: Overview > Proteoglycans in cancer.

· Human Diseases > Cancers: Overview > MicroRNAs in cancer.

· Human Diseases > Cancers: Specific types > Colorectal cancer.   (View pathway)

· Human Diseases > Cancers: Specific types > Renal cell carcinoma.   (View pathway)

· Human Diseases > Cancers: Specific types > Pancreatic cancer.   (View pathway)

· Human Diseases > Cancers: Specific types > Endometrial cancer.   (View pathway)

· Human Diseases > Cancers: Specific types > Glioma.   (View pathway)

· Human Diseases > Cancers: Specific types > Prostate cancer.   (View pathway)

· Human Diseases > Cancers: Specific types > Thyroid cancer.   (View pathway)

· Human Diseases > Cancers: Specific types > Melanoma.   (View pathway)

· Human Diseases > Cancers: Specific types > Bladder cancer.   (View pathway)

· Human Diseases > Cancers: Specific types > Chronic myeloid leukemia.   (View pathway)

· Human Diseases > Cancers: Specific types > Acute myeloid leukemia.   (View pathway)

· Human Diseases > Cancers: Specific types > Non-small cell lung cancer.   (View pathway)

· Human Diseases > Cancers: Specific types > Breast cancer.   (View pathway)

· Human Diseases > Cancers: Specific types > Hepatocellular carcinoma.   (View pathway)

· Human Diseases > Cancers: Specific types > Gastric cancer.   (View pathway)

· Human Diseases > Cancers: Overview > Central carbon metabolism in cancer.   (View pathway)

· Human Diseases > Cancers: Overview > Choline metabolism in cancer.   (View pathway)

· Organismal Systems > Immune system > Chemokine signaling pathway.   (View pathway)

· Organismal Systems > Circulatory system > Vascular smooth muscle contraction.   (View pathway)

· Organismal Systems > Development > Osteoclast differentiation.   (View pathway)

· Organismal Systems > Immune system > Toll-like receptor signaling pathway.   (View pathway)

· Organismal Systems > Immune system > Natural killer cell mediated cytotoxicity.   (View pathway)

· Organismal Systems > Immune system > T cell receptor signaling pathway.   (View pathway)

· Organismal Systems > Immune system > B cell receptor signaling pathway.   (View pathway)

· Organismal Systems > Immune system > Fc epsilon RI signaling pathway.   (View pathway)

· Organismal Systems > Immune system > Fc gamma R-mediated phagocytosis.   (View pathway)

· Organismal Systems > Nervous system > Long-term potentiation.

· Organismal Systems > Nervous system > Neurotrophin signaling pathway.   (View pathway)

· Organismal Systems > Nervous system > Cholinergic synapse.

· Organismal Systems > Nervous system > Serotonergic synapse.

· Organismal Systems > Nervous system > Long-term depression.

· Organismal Systems > Endocrine system > Insulin signaling pathway.   (View pathway)

· Organismal Systems > Endocrine system > Progesterone-mediated oocyte maturation.

· Organismal Systems > Endocrine system > Estrogen signaling pathway.   (View pathway)

· Organismal Systems > Endocrine system > Melanogenesis.

· Organismal Systems > Endocrine system > Prolactin signaling pathway.   (View pathway)

· Organismal Systems > Endocrine system > Thyroid hormone signaling pathway.   (View pathway)

· Organismal Systems > Endocrine system > Oxytocin signaling pathway.

· Organismal Systems > Endocrine system > Relaxin signaling pathway.

文献引用

1). Serum proteomics analysis based on label-free revealed the protective effect of Chinese herbal formula Gu-Ben-Fang-Xiao. BIOMEDICINE & PHARMACOTHERAPY, 2019 (PubMed: 31520916) [IF=6.9]

Application: WB    Species: mouse    Sample: lung

Figure S2. |The effect of GBFXD on RAF/MEK/ERK signaling pathway. Western blotting was used to detect the relative protein expressions of P-RAF/RAF, P-MEK/MEK, and P-ERK/ERK.
2). Tanshinone IIA inhibits cardiomyocyte apoptosis and rescues cardiac function during doxorubicin-induced cardiotoxicity by activating the DAXX/MEK/ERK1/2 pathway. Phytomedicine, 2022 (PubMed: 36182795) [IF=6.7]
3). NCAPD3 contributes to lung cancer progression through modulated lactate-induced histone lactylation and MEK/ERK/LDHA axis. Cancer cell international, 2025 (PubMed: 40410796) [IF=5.8]

Application: WB    Species: human    Sample: LC cells

Fig. 4 NCAPD3 regulated aerobic glycolysis in LC cells through the MEK/ERK/LDHA signaling pathway. (A) The protein levels of MEK/ERK pathway-associated targets were detected by western blotting in NCAPD3-knockdown H1975 cells and NCAPD3-over-expression HCC827 cells. (B) Cell proliferation in HCC827 cells treated with U0126 (50 µM) and NCAPD3 overexpression plasmids in alone or combination was assessed by a colony formation assay. (C) Glucose uptake in HCC827 cells treated with U0126 (50 µM) and NCAPD3 overexpression plasmids in alone or combination was assessed by Flow cytometry. (D) The lactate levels in HCC827 cells treated with U0126 (50 µM) and NCAPD3 overexpression plasmids in alone or combination were assessed by the Lactic Acid (LA) Content Assay Kit. (E) The protein expression levels of HK2, PKM2, GLUT1, LDHA, p-MEK, MEK, p-ERK, and ERK in HCC827 cells treated with U0126 (50 µM) and NCAPD3 overexpression plasmids in alone or combination were detected through western blotting. ▲P 
4). Wenshen-Jianpi prescription, a Chinese herbal medicine, improves visceral hypersensitivity in a rat model of IBS-D by regulating the MEK/ERK signal pathway. Frontiers in Pharmacology, 2022 (PubMed: 36210803) [IF=5.6]
5). β-Patchoulene Ameliorates Water Transport and the Mucus Barrier in 5-Fluorouracil-Induced Intestinal Mucositis Rats via the cAMP/PKA/CREB Signaling Pathway. Frontiers in Pharmacology, 2021 (PubMed: 34512326) [IF=5.6]

Application: WB    Species: Rat    Sample:

FIGURE 5 Effects of β-PAE on AQP3 expression and cAMP/PKA/CREB signaling pathway-related proteins. (A,B) AQP3 expression; (C,D) VIP, VIPR2, cAMP and PKA expression; (E,F) MEK1/2, p-MEK1/2, ERK, p-ERK, p-p38, p38, MSK1, p-MSK1, CREB, p-CREB, and P300/CBP expression. Data are shown as mean ± SD (n = 3). # p < 0.05, ## p < 0.01 versus control group; * p < 0.05, ** p < 0.01 versus 5-FU group.
6). Antimalarial drug pyrimethamine plays a dual role in anti-tumor proliferation and metastasis through targeting DHFR and TP. MOLECULAR CANCER THERAPEUTICS, 2019 (PubMed: 30642883) [IF=5.3]

Application: WB    Species: human    Sample: NCI-H460 cells

Figure 6.| Pyr can bind to TP and inhibit TP-induced migration, invasion, and EMT of lung cancer cells. (A) Molecular docking results for TP and Pyr. (B) Thymine concentration of NCI-H460 cells treated with 5-UIR, Pyr, and MTX. Intercellular thymine concentration was used as an index of TP activity. (C) Interaction between Pyr and TP verified through Biacore assay (Kd=6.19±0.78 μM). (D) Pyr can inhibit the TP-induced migration of cancer cells. Wound-healing assay was used in this experiment. (E) Pyr can inhibit the TP-induced invasion of cancer cells. Transwell chambers were utilized for the invasion assay, and images were obtained under 200× magnification. (F) E-cadherin, vimentin, MEK2, and ERK2 expression levels of NCI-H460 cells in different treatment groups. The GAPDH blot served as the loading control. Data are presented as the means of three experiments, and error bars represent the standard deviation (*P < 0.05, **P < 0.01)
7). Exercise-induced endothelial Mecp2 lactylation suppresses atherosclerosis via the Ereg/MAPK signalling pathway. Atherosclerosis, 2023 (PubMed: 37245426) [IF=4.9]
8). l-Theanine attenuates neointimal hyperplasia via suppression of vascular smooth muscle cell phenotypic modulation. JOURNAL OF NUTRITIONAL BIOCHEMISTRY, 2020 (PubMed: 32402912) [IF=4.8]
9). EphA10 drives tumor progression and immune evasion by regulating the MAPK/ERK cascade in lung adenocarcinoma. International Immunopharmacology, 2022 (PubMed: 35839564) [IF=4.8]
10). Intra-Pancreatic Insulin Nourishes Cancer Cells: Do Insulin-Receptor Antagonists such as PGG and EGCG Play a Role?. The American Journal of Chinese Medicine, 2020 (PubMed: 32468825) [IF=4.8]

Application: WB    Species: Mice    Sample: tumors tissue

Figure 4. See the legend of Fig. 3 for study design. (A, B) t-Akt and p-Akt results from the sub-studies that involved PGG (A) and EGCG (B). (C, D) t-MEK and p-MEK results from the sub-studies that involved PGG (C) and EGCG (D). (E, F) t-ERK1/2 and p-ERK1/2 results from the sub-studies that involved PGG (E) and EGCG (F). β-Actin was used as a loading control. The blotting data are derived from representative tumors. The histograms include data from all tumors. *p < 0:05.
加载更多

限制条款

产品的规格、报价、验证数据请以官网为准，官网链接：www.affbiotech.com | www.affbiotech.cn（简体中文）| www.affbiotech.jp（日本語）

产品的数据信息为Affinity所有，未经授权不得收集Affinity官网数据或资料用于商业用途，对抄袭产品数据的行为我们将保留诉诸法律的权利。

产品相关数据会因产品批次、产品检测情况随时调整，如您已订购该产品，请以订购时随货说明书为准，否则请以官网内容为准，官网内容有改动时恕不另行通知。

Affinity保证所销售产品均经过严格质量检测。如您购买的商品在规定时间内出现问题需要售后时，请您在Affinity官方渠道提交售后申请。

产品仅供科学研究使用。不用于诊断和治疗。 

产品未经授权不得转售。

Affinity Biosciences将不会对在使用我们的产品时可能发生的专利侵权或其他侵权行为负责。Affinity Biosciences, Affinity Biosciences标志和所有其他商标所有权归Affinity Biosciences LTD.